George Elston - 03 Jan 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
03 Jan 2025
Net transactions value
-$85,239
Form type
4
Filing time
07 Jan 2025, 16:04:14 UTC
Previous filing
28 May 2024
Next filing
11 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +15,000 +31% $0.000000 63,356 05 Jan 2025 Direct F1
transaction EYPT Common Stock Tax liability $43,505 -5,267 -8.3% $8.26 58,089 05 Jan 2025 Direct F2
transaction EYPT Common Stock Options Exercise $0 +15,285 +26% $0.000000 73,374 06 Jan 2025 Direct
transaction EYPT Common Stock Tax liability $41,733 -4,808 -6.6% $8.68 68,566 06 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +59,000 +393% $0.000000 74,000 03 Jan 2025 Common Stock 59,000 $0.000000 Direct F3
transaction EYPT Stock Option (Right to Buy) Award $0 +117,000 $0.000000 117,000 03 Jan 2025 Common Stock 117,000 $8.26 Direct F4
transaction EYPT Restricted Stock Units Options Exercise $0 -15,000 -33% $0.000000 30,000 05 Jan 2025 Common Stock 15,000 $0.000000 Direct F5
transaction EYPT Restricted Stock Units Options Exercise $0 -15,285 -51% $0.000000 14,715 06 Jan 2025 Common Stock 15,285 $0.000000 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 876 shares acquired on July 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F3 The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.
F4 The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.
F5 The restricted stock units vests in three ratable annual installments beginning January 5, 2025.
F6 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.